A $360M Round With No Equity Strings Attached
The beauty and wellness industry just witnessed a landmark funding moment. Musely, a direct-to-consumer brand specializing in skin care, hair care, and menopause wellness, has secured $360 million from prominent venture capital firm General Catalyst — and remarkably, the company didn't have to give up ownership to get it.
The term "non-dilutive capital" is the real headline here. Unlike a traditional equity round — where a startup sells a percentage of itself in exchange for cash — non-dilutive financing means Musely pockets the money without ceding any stake. These structures, which often take the form of revenue-based financing or structured credit agreements, see investors repaid through a portion of future revenues rather than equity.
For founders, this distinction is enormous. Dilution is one of the most painful trade-offs in startup growth: every new funding round chips away at the founding team's ownership. By securing one of the largest non-dilutive rounds in the DTC wellness space, Musely's leadership preserved their cap table while still gaining the fuel they need to scale.
What Musely Actually Does
Musely operates at the intersection of telehealth and DTC beauty, offering prescription-strength and science-backed treatments for skin conditions, hair loss, and menopause symptoms — all delivered directly to consumers through a digital platform. Customers consult with licensed providers online and receive personalized treatment plans shipped to their door.
This model has exploded in popularity as consumers increasingly favour the convenience of virtual consultations over in-person dermatology visits, particularly for conditions that carry social stigma or simply don't require a physical exam. The category has seen fierce competition from players like Hims & Hers and Ro, making capital — and how cleanly you hold on to it — a key battleground.
Supercharging Customer Acquisition
Musely plans to deploy the $360 million squarely on customer acquisition — pouring resources into marketing, digital advertising, and expanding its addressable audience. In a crowded DTC market where brands are competing aggressively for the same online eyeballs, having a war chest of this size without the dilution burden gives Musely a meaningful structural edge over rivals who had to trade equity for their growth capital.
Why This Deal Structure Matters
General Catalyst's willingness to deploy at this scale on non-dilutive terms signals strong confidence in Musely's revenue trajectory and ability to repay through future performance. The firm — one of the most active in U.S. health tech and consumer health — has been increasingly drawn to models where lifetime customer value is high and the unit economics can support structured repayment.
The deal also reflects a broader shift in how growth-stage companies think about financing. As traditional equity rounds face more scrutiny in tighter markets, revenue-based and non-dilutive structures are gaining ground, especially in DTC health where customer acquisition costs are steep but repeat purchase behaviour can be strong.
The Bigger Picture
For Musely, the $360 million positions the company to push harder on its core mission: making prescription-strength treatments more accessible, affordable, and convenient — without handing the keys to outside investors. It's a rare outcome in venture financing, and one that other founders in the consumer health space will be watching closely.
Source: TechCrunch
